A Safety and Efficacy Study of Xolair in Peanut Allergy
This study has been terminated.
Information provided by (Responsible Party):
First received: July 6, 2004
Last updated: January 17, 2013
Last verified: January 2013
This is a 38-week, randomized, double-blind, placebo-controlled, parallel group trial of approximately 150 patients who have a history of immediate hypersensitivity reaction to peanut protein.
|Study Design:||Primary Purpose: Treatment|
|Official Title:||A Phase II, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Oral Food Challenge Trial of Xolair (Omalizumab) in Peanut Allergy|
Resource links provided by NLM:
Further study details as provided by Genentech:
Contacts and Locations